
欧洲表阿霉素市场预测至 2028 年 – COVID-19 影响和区域分析 – 按剂量(10 毫克/瓶、50 毫克/瓶、100 毫克/瓶和 200 毫克/瓶)、应用(乳腺癌、肝癌、膀胱癌)等)和分销渠道(医院药房、零售药房和在线药房)
No. of Pages: 107 | Report Code: BMIRE00027256 | Category: Life Sciences
No. of Pages: 107 | Report Code: BMIRE00027256 | Category: Life Sciences
欧洲表阿霉素市场预计将从2022年的51,079.61万美元增长到2028年的62,495.08万美元;预计 2022 年至 2028 年复合年增长率为 3.4%。
人们对癌症的认识不断提高,推动了表阿霉素市场的发展
3 月 8 日, 2021 年,世界卫生组织推出了全球乳腺癌倡议,目标是到 2040 年每年将乳腺癌死亡率降低 2.5%,从而避免约 2500 人死亡。世界卫生组织在国际妇女节当天的一场名为“倾听乳腺癌女性的呼声”的宣传活动中提出了这一倡议。同样,世界卫生组织于 2018 年 9 月启动了儿童癌症全球倡议,旨在到 2030 年将癌症儿童的生存率提高约 60%,同时减少这些儿童的痛苦并提高他们的生活质量。自 2000 年以来,每年 2 月 4 日举办的世界癌症日是由国际癌症控制联盟 (UICC) 领导的联合倡议。 UICC 致力于提高全球癌症意识;改善教育;促进个人、集体和政府的行动;共同努力预防癌症死亡。因此,通过各种举措提高癌症意识正在推动整个欧洲表柔比星市场的发展。
市场概览
span>
由于癌症患病率上升以及对开发新化疗方案的高需求等因素,欧洲在表阿霉素市场中占据第二大份额药物。市场增长归因于药品产量的增加、制药公司不断增长的产品创新、政府支持的增加以及生产设施和基础设施的发展。此外,用于研究和开发的资金不断增加。制药行业的开发活动可能在未来几年提供许多机会。英国的制药业正在不断扩张。根据英国国家统计局的数据,2018 年有 610 家公司在英国开展业务,其中超过 15 家跨国公司的总部设在英国。此外,大约41%的药品生产出口到其他欧洲国家和地区。阿斯利康 (Astra Zeneca)、礼来 (Eli Lilly) 和葛兰素史克 (GSK) 等公司通过领先的研究和开发,为制药业的增长做出了重大贡献。发展活动。这些公司的增长预计将影响未来几年的市场增长。而且,英国90岁以上人群的乳腺癌发病率最高。根据英国国家统计局的国家统计数据,2019 年,约有 605,181 人年龄在 90 岁及以上。此外,根据英国癌症研究中心的数据,英国每年约有 55,900 例新乳腺癌病例。因此,不断增长的老年人口可能会增加乳腺癌的发病率。因此,上述因素正在推动表阿霉素市场的增长。
欧洲表阿霉素市场收入及预测2028(千美元)
< span>
欧洲表柔比星市场根据剂量、应用、分销渠道和国家/地区进行细分
Fresenius Kabi AG、Hikma Pharmaceuticals PLC、Mylan NV、Pfizer Inc.、Salius Pharma Pvt Ltd、和 Teva Pharmaceutical Industries Ltd. 是欧洲表阿霉素市场的领先公司。
Strategic insights for Europe Epirubicin involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 51,079.61 thousand |
Market Size by 2028 | US$ 62,495.08 thousand |
Global CAGR (2022 - 2028) | 3.4% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 剂量
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Epirubicin refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Epirubicin Market is valued at US$ 51,079.61 thousand in 2022, it is projected to reach US$ 62,495.08 thousand by 2028.
As per our report Europe Epirubicin Market, the market size is valued at US$ 51,079.61 thousand in 2022, projecting it to reach US$ 62,495.08 thousand by 2028. This translates to a CAGR of approximately 3.4% during the forecast period.
The Europe Epirubicin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Epirubicin Market report:
The Europe Epirubicin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Epirubicin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Epirubicin Market value chain can benefit from the information contained in a comprehensive market report.